A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

What Was Tested

In this phase 3 trial, researchers set out to test Insulin Glargine and Insulin Lispro.

The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period.

The study will last up to 34 weeks.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 730 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a diagnosis of T2D according to the world health organization (WHO) criteria, currently treated with basal insulin and at least 2 injections of prandial insulin per day. Once daily U-100 or U-200 insulin degludec. Once daily U-100 or U-300 insulin glargine. Once or twice daily U-100 insulin detemir or. Once or twice daily human insulin Neutral Protamine Hagedorn.

The full record lists 21 inclusion and 12 exclusion criteria; among the exclusions: are currently receiving any of the following insulin therapies anytime in the past 90 days:; insulin mixtures; insulin human, inhalation powder, or.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Because people in this Insulin Glargine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Being open-label, the Insulin Glargine study did not mask who received what.

It started in 2022-08-11 with completion listed for 2024-02-27.

It ran at 81 sites in United States (24), Argentina (16), Spain (12), Italy (8), Germany (7) and India (6).

Its stated primary purpose is treatment.

What Was Measured

It also tracked 15 secondary outcomes, for example Nocturnal Hypoglycemia Event Rate, Change From Baseline in Fasting Glucose, Percentage of Time in Glucose Range, Percentage of Time in Hypoglycemia Range, Percentage of Time in Hyperglycemia Range and Glucose Variability Between Weeks 22 to 26.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Insulin Glargine and Insulin Lispro in 730 people.

With 730 participants it is a large trial for this field.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Insulin Glargine compound page and the Insulin Lispro compound page, all human trials.